Supply Chain

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, describes the progression of the sample distribution process.

The program intends to address supply chain challenges surrounding product safety, traceability, and counterfeiting.

The Drug Supply Chain Security Act was a major coverage area for Pharma Commerce in 2024.

How will supply chains in the space continue to develop?

In the fifth part of this roundtable discussion, subject matter experts discuss the role that various GS1 initiatives have played, and provide a breakdown of stakeholders who have benefitted greatly from RFID.

As a result, the provider increases its involvement in the country’s pharma sector.

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia.

In the fourth part of this roundtable discussion, key opinion leaders discuss how successful RFID use cases in the food sector can translate well to pharma, including what needs to be implemented in order to see success.

A session investigates the drivers of these shortages and ways to mitigate them.

The seminar focuses on US supply chain resiliency, while remaining compliant and preserving patient access.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

A panel uncovers how distribution channels are aligning commercialization efforts.

The value of this sometimes-unheralded technology to the pharma industry—as well as potential use cases—are starting to come to light.

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, predicts the probability that these DSCSA compliance deadlines put forth by the FDA will be met.

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.

In the third part of this roundtable discussion, experts discuss the value of Michigan State University’s Axia Institute—including its RFID testing efforts—and dive into the Institute’s end-to-end RFID pilot that it has been conducting.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, describes the latest state of DSCSA implementation guidelines.

A total of 140 companies are being placed on the Entity List, in an effort to limit China’s effectiveness in the sector.

The transaction reaffirms the CDMO’s interest in growth on a global scale.

Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.

In the second part of this roundtable discussion, key opinion leaders discuss the potential technological challenges surrounding RFID, and the likelihood of not only utilizing this tech at the item level but for product security purposes as well.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, outlines the steps that pharma leaders should keep in mind to when combatting supply chain issues.

The collaboration is centered on standardization and the promotion of safety data sharing when it comes to ground handling.